Search Results
Your search for ,wAS matches 27420 pages
Showing 5251 - 5300
Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small...
NCI Director Monica M. Bertagnolli, MD, FACS, FASCO, Announces Breast Cancer Diagnosis
On December 14, Monica M. FACS, Bertagnolli, MD, FASCO, Director of the National Cancer Institute (NCI), released the following statement: I was very recently diagnosed with early breast cancer. The prognosis is very favorable. The cancer is hormone receptor–positive, HER2-negative breast cancer...
Scientists Map Genetic Evolution of CLL to Richter Syndrome
Richter syndrome is an aggressive lymphoma that develops in up to 1% of patients with chronic lymphocytic leukemia (CLL) and it serves as an example of histologic transformation. While recent advances have transformed the treatment landscape of CLL, Richter syndrome remains associated with poor...
Zanubrutinib Found Superior to Ibrutinib for CLL and SLL
Zanubrutinib showed superior efficacy to ibrutinib—with fewer side effects—in the first head-to-head comparison between the Bruton’s tyrosine kinase (BTK) inhibitors among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to data presented by Jennifer...
Venetoclax With Intensive Chemotherapy Regimen May Be Effective in Younger Patients With Newly Diagnosed AML, High-Risk Myelodysplastic Syndrome
A novel study evaluating the addition of venetoclax to the intensive chemotherapy regimen of cladribine, idarubicin, and cytarabine as a front-line therapy demonstrated high rates of disease control and remissions in younger patients with newly diagnosed acute myeloid leukemia (AML) and high-risk...
Chemotherapy-Free Regimen of Ponatinib and Blinatumomab May Be Effective for Patients With Newly Diagnosed Philadelphia Chromosome–Positive ALL
A new phase II trial demonstrated that the chemotherapy-free regimen of ponatinib and blinatumomab may have achieved high response rates and reduced the need for an allogeneic stem cell transplant for patients with recently diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic...
Older or High-Risk Patients With Newly Diagnosed AML May Respond to Triplet Therapy
Researchers observed encouraging response rates in older or high-risk patients with newly diagnosed acute myeloid leukemia (AML) when treated with the triplet combination therapy of azacitidine, venetoclax, and magrolimab in a phase I/II trial, according to new findings presented by Daver et al at...
Blinatumomab Further Improves Survival Among Patients With B-Lineage ALL and a Good Prognosis
The bispecific T-cell engager molecule blinatumomab was found to improve overall survival for patients with no measurable residual disease (MRD) after initial treatment for B-lineage acute lymphoblastic leukemia (ALL), according to the phase III ECOG-ACRIN E1910 trial presented by Litzow et al at...
Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
The use of a simplified treatment regimen by oncologists—along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts—resulted in a decrease in early deaths from acute promyelocytic leukemia (APL). In the multicenter prospective trial...
Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS Lymphoma
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel was deemed safe and showed encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, according to findings presented by Caron A. Jacobson, MD, MMSc, and colleagues ...
New Clinical Tool for Clonal Hematopoiesis May Identify Patients at High Risk for Hematologic Cancer
A new clinical tool may pinpoint which patients with clonal hematopoiesis are at highest risk for cancer progression, according to new findings presented by Weeks et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 926). Background Clonal hematopoiesis—a...
Three-Drug Combination Therapy May Be Effective in Patients With High-Risk CLL
A three-drug combination that showed success at sending patients with chronic lymphocytic leukemia (CLL) into deep remissions in a clinical trial may be effective at treating patients with high-risk types of the disease, according to new findings presented by Ryan et al at the 2022 American Society ...
TAILORx Update: 12-Year Recurrence and Survival Outcomes for Patients With Early-Stage Breast Cancer
Long-term recurrence and survival data are now available from the groundbreaking TAILORx trial. With 12 years of follow-up, the updated analysis—reported by Sparano et al at the San Antonio Breast Cancer Symposium (SABCS) 2022 (Abstract GS1-05)—confirms the original findings that chemotherapy may...
FDA Grants Accelerated Approval to Adagrasib for KRAS G12C–Mutated NSCLC
On December 12, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati), a RAS GTPase family inhibitor, for adult patients with KRAS G12C–mutated, locally advanced or metastatic non–small cell lung cancer (NSCLC), as determined by an FDA-approved test, who...
Global Study Uncovers Regional Differences in the Use of Curative Transplants for Patients With AML
The use of stem cell transplantation for acute myeloid leukemia increased by about 55% worldwide from 2009 to 2016, according to new findings presented by Niederweiser et al at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 3638). Although the largest...
Identifying Which Patients Receive the Most Specialized Types of Stem Cell Transplant Requiring the Highest Level of Care
Patients of non-European ancestry and especially those of low socioeconomic status are more likely to receive the most specialized types of allogeneic stem cell transplantation that require the highest level of care, according to new findings presented by Fingrut et al at the 2022 American Society...
Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends
Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute...
Study Finds Adult Survivors of Pediatric Hodgkin Lymphoma Experience Significant Epigenetic Age Acceleration Associated With Neurocognitive Deficits
Research shows that long-term survivors of pediatric Hodgkin lymphoma are at an elevated risk for a variety of health conditions, including cardiopulmonary morbidity, cognitive impairment, and premature death, and could also be at heightened risk for the premature onset of dementia. A new study of...
Clinical Trial Lab-Based Eligibility Criteria Disproportionately Excluded Non-White Patients With DLBCL From Study Participation
A previous analysis by Khurana et al on the impact of inclusion/exclusion criteria in clinical trial design for patients with diffuse large B-cell lymphoma (DLBCL) found that up to 24% of patients treated with standard immunochemotherapy were excluded based on five lab-based criteria alone. A new...
Kathryn R. Tringale, MD, on Primary CNS Lymphoma: Initial Treatment Response in More Than 500 Patients
Kathryn R. Tringale, MD, of Memorial Sloan Kettering Cancer Center, discusses an assessment of 559 patients with primary central nervous system (CNS) lymphoma and the factors associated with consolidation therapy selection, outcomes after consolidation therapy accounting for patient factors, and...
Targeting Menin May Induce Responses in Patients With Acute Leukemias and KMT2A Rearrangements or NPM1 Mutations
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with an oral small-molecule inhibitor of the menin-KMT2A interaction, SNDX-5613—now named revumenib—yielded encouraging responses for patients with advanced acute leukemias and KMT2A rearrangements or...
Jorge E. Cortes, MD, on CML: Efficacy and Safety of Vodobatinib
Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discusses new findings on vodobatinib, which was administered to patients with chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia (CML) and appeared to be efficacious and safe in people who had received...
Eunice S. Wang, MD, on AML: Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses the outcomes of patients newly diagnosed with acute myeloid leukemia (AML) who were treated with cytarabine plus daunorubicin plus gemtuzumab ozogamicin (GO). These patients experienced higher rates of measurable residual...
Efficacy of Sacituzumab Govitecan in TROPiCS-02 Trial Not Dependent on Trop-2 Expression
The latest analysis of the TROPiCS-02 breast cancer trial shows that sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio Breast Cancer Symposium by Hope S. Rugo, MD, FASCO, Professor of Medicine and...
MonarchE Update: Benefit of Abemaciclib Increases Over Time
Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk breast cancer, according to Stephen R.D....
Survey Finds Sexuality and Fertility Discussions Remain Sidelined Among Young Patients Diagnosed With Breast Cancer
In a new survey, a majority (64%) of patients diagnosed with breast cancer younger than 46 years reported significant impacts to their sexual health, yet 86% of patients reported that their health-care provider was unable to help address sexual health issues, according to findings presented by...
High-Dose Methotrexate May Make Posttreatment Steroids Unnecessary for Some Pediatric Patients With ALL or LBL
The results of a new study answer some questions and raise new ones about the optimal treatment strategy for children and young adults living with acute lymphoblastic leukemia (ALL) or lymphoblastic leukemia (LBL). The randomized study is the first to test whether the use of a shorter, higher-dose...
Talquetamab Generates High Response Rate in Relapsed or Refractory Multiple Myeloma
In an early-phase trial, nearly three-quarters of patients who received talquetamab—a first-in-class, off-the-shelf, T-cell–redirecting bispecific antibody targeting both the GPRC5D and CD3 receptors—for relapsed or refractory multiple myeloma saw a significant reduction in cancer burden within a...
Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy
Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and...
Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy
Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier...
Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative, advanced or metastatic breast cancer...
Study Explores When to Proceed to Stem Cell Transplantation for Patients With Resistant AML
Patients with acute myeloid leukemia (AML) whose disease relapsed or did not respond to initial chemotherapy had similar outcomes when they proceeded directly to allogeneic stem cell transplantation compared with those who underwent intensive salvage chemotherapy to achieve complete remission...
Will Ibrutinib Replace Stem Cell Transplantation as First-Line Treatment for Mantle Cell Lymphoma?
In a recent trial of the European MCL Network, people with mantle cell lymphoma who received the Bruton’s tyrosine kinase inhibitor ibrutinib had rates of progression-free survival and overall survival that were on par with the current standard of care (high-dose immunochemotherapy followed by...
Impact on Cognitive Function of Adding Chemotherapy to Endocrine Therapy for Breast Cancer
Chemotherapy followed by endocrine therapy led to more cancer-related cognitive impairment compared with endocrine therapy alone in patients with hormone receptor–positive, HER2-negative breast cancer at 36 months, according to patient-reported responses. These findings—from a substudy of the phase ...
Genetic Profiling May Identify Patients With Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-Conserving Surgery
Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had similar rates of local recurrence independent of whether they received adjuvant radiation therapy after breast-conserving surgery, according to findings presented by Karlsson et al at the 2022 ...
Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions
Patients with multiple tumors in a single breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to new findings presented by Judy C. Boughey, MD, and colleagues at the 2022 San...
FDA Grants Approval to Atezolizumab in Treatment of Alveolar Soft-Part Sarcoma
On December 9, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft-part sarcoma (ASPS). Study ML39345 Efficacy was evaluated in Study ML39345...
Putting the Patient at the Center: The Career of Jeffery Ward, MD, FASCO
Editor’s Note: ASCO was deeply saddened by the news that Dr. Jeff Ward passed away on November 3, 2022. In an interview with Dr. Ward this past summer, published in ASCO Connection (August 30, 2022), ASCO recognized Dr. Ward’s commitment to exceptional patient care and public advocacy. An...
I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
Experimental Drug Under Study in Liver Cancer
A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer who have been treated unsuccessfully previously with up to three lines of treatment. These findings were presented...
AKT Inhibitor Shows Signs of Activity in a Trial Matching Drugs to Tumor Gene Mutations
In a trial matching the genetic makeup of tumors with new treatments, tumors shrank in 22% of patients with cancer who received the AKT inhibitor ipatasertib. Participants included those with breast cancer and endometrial cancer as well as those with two rarer types of cancer, anal and salivary...
Liquid Biopsies May Identify Patients With Cancer at Higher Risk of Developing Additional Blood Cancers
Researchers have found that liquid biopsies may be able to detect the blood disorder clonal hematopoiesis, which places patients at higher risk of developing blood cancers. The findings were presented at the 2022 European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer...
Pregnancy Confers ‘Dual Effect’ on Breast Cancer Risk
“Pregnancy confers a dual effect” on breast cancer risk, “with an initial transient increased risk for breast cancer that is followed by long-term protection over time,” Luis Zabala Blanco, Jr, MD, noted in an update on the pathology of pregnancy-associated breast cancer, which was presented at the ...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
World Travel Helped Brittany L. Bychkovsky, MD, MSc, Shape Her Global Commitment to Breast Cancer Care
Breast cancer specialist Brittany L. Bychkovsky, MD, MSc, grew up primarily in Kansas; however, given that her father was a pilot, her childhood was not wholly centered in the Sunflower State. “When I was 12 years old, my mom, who was a schoolteacher, was diagnosed with stage III breast cancer. Her ...
2022 Society for Integrative Oncology Annual International Conference
Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its 2022 Annual International Conference in a hybrid format (virtual and in Scottsdale, Arizona). It was centered on the basic science, education and training, and implementation of integrative oncology in diverse...
Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer
Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone...
Cemiplimab/Chemotherapy Combination in Advanced NSCLC With No EGFR, ALK, or ROS1 Aberrations
On November 8, 2022, cemiplimab-rwlc was approved for use in combination with platinum-based chemotherapy for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.1 Supporting Efficacy Data Approval was supported by findings in the ...
Teclistamab in the Treatment of Relapsed or Refractory Multiple Myeloma
On October 25, 2022, the bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager teclistamab-cqyv was granted accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome...
The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer
The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...
